BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36123452)

  • 1. Clinical and prognostic role of 2-[
    Tan X; Yuan H; Li D; Sun X; Ding C; Jiang L
    Ann Hematol; 2022 Dec; 101(12):2699-2709. PubMed ID: 36123452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of
    Yuan H; Tan X; Sun X; He L; Li D; Jiang L
    Jpn J Radiol; 2023 May; 41(5):521-530. PubMed ID: 36480105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer.
    Li D; Tan X; Yuan H; Yao X; Sun X; He L; Jiang L
    Nucl Med Commun; 2023 Apr; 44(4):309-317. PubMed ID: 36756769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18 F-fluorodeoxyglucose PET/computed tomography metabolic parameters and sarcopenia in pancreatic cancer.
    Zhang Q; Ren J; Tan X; He M; Qiu T; Jiang L
    Nucl Med Commun; 2023 Aug; 44(8):719-725. PubMed ID: 37334539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of body composition and metabolic parameters extracted from baseline
    Chen Y; Chen Z; Tan X; Zhang Q; Zhou Y; Yuan H; Jiang L
    Ann Hematol; 2023 Oct; 102(10):2779-2789. PubMed ID: 37530853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of baseline
    Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
    Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
    Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline [
    Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
    Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
    Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
    Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
    Dai N; Liu H; Deng S; Sang S; Wu Y
    Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
    Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
    BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.